<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":4934,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/3a432f917f0c603aa8163a5e2ca2263e'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/3a432f917f0c603aa8163a5e2ca2263e'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1HPS3A003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HPS3A003">Previous Result: <span>D Ã­az v. Plan de Bienestar UTM-PRSSA, In...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1HPRK8003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HPRK8003">Next Result: <span>Bank of America, N.A. v. Arriola, Case N...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), Court Opinion'>
Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), Court Opinion</div>
<div class='docId'>X1HPS70003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Public Pension Fund Group v. KV Pharmaceutical Co.</div>
<div class='displayCitation'>2012 BL 135462</div>
<div class='displayCitation'>679 F.3d 972</div>
<div class='displayCitation'>bna a0d2z7j4c3</div>
<div class='displayCitation'>bna a0e3q3w5p8</div>
<div class='displayCitation'>wkf8case:26114160</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HPS70003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Public Pension Fund Group v. KV Pharmaceutical Co." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1HPS70003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HPS70003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HPS70003" /><input id="title" name="title" type="hidden" value="Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="3a432f917f0c603aa8163a5e2ca2263e" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HPS70003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%33a%34%33%32f%39%31%37f%30c%36%30%33aa%38%31%36%33a%35e%32ca%32%32%36%33e%2Fdocument%2FX%31HPS%37%30%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/bcite/X1HPS70003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/bcite/X1HPS70003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/bcite/X1HPS70003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/related_content/X1HPS70003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1711417589763";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">679 F.3d 972</div>
<div class="cite" data-cite-type="DocketNumber">10-3402</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 135462</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Eighth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
PUBLIC PENSION FUND GROUP; Herman Unvericht; Norfolk County Retirement
System; Joseph Mas; Building Trades United Pension Trust Fund; New Jersey
Carpenters Pension Fund, Appellants, v. KV PHARMACEUTICAL COMPANY; Marc S.
Hermelin; David A. Van Vliet; Rita E. Bleser, Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-3402.
</center></p>
<p><center>
Submitted: September 22, 2011.
</center></p>
<p><center>
Filed: June 4, 2012.
</center></p>
<div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Eastern District of
Missouri, <span CLASS="page_no" data-cite="679 f 3d 975" data-cite-type="PrimaryFederalReporter" data-cite-pageno="975" data-primary-citation="679 F.3d 972">[*975]</span> Carol E. Jackson, J.

[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
Javier Bleichmar, argued, New York, NY, Michael D. Murphy, Jason Glennon
Crowell, Ted R. Osburn, Cape Girardeau, MO, Christopher J. Keller, Alan I.
Ellman, Joseph A. Fonti, Stephen W. Tountas, New York, NY, on the brief, for
Appellant.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Jeffrey Edward McFadden, argued, Patrick F. Linehan, Shawn Patrick Davisson,
on the brief, Washington, DC, for Appellee Marc S. Hermelin.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Andrew S. Tulumello, argued, Washington, DC, Kurtis B. Reeg, Timothy
Alexander McGuire, on the brief, St. Louis, MO, for Appellee Rita E. Bleser.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Andrew S. Tulumello, argued, Washington, DC, Robert P. Berry, on the brief,
St. Louis, MO, F. Joseph Warin, Jennifer J. Schulp, Jason E. Morrow,
Washington, DC, on the brief, for Appellee KV Pharmaceutical Company and
David A. Van Vliet.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before WOLLMAN, BYE, and SHEPHERD, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
BYE, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

Several groups of investors<a HREF="#fn100" name="fnref_fn100">[fn1]</a> who purchased the securities of KV
Pharmaceutical Company (KV) brought this class action lawsuit alleging KV
and some of its individual officers committed securities fraud. The
investors alleged KV made false or misleading statements about its
compliance with Food and Drug Administration (FDA) regulations governing the
manufacture of pharmaceutical products, and made false or misleading
statements about earnings resulting from pharmaceutical products allegedly
manufactured in violation of FDA regulations. The district court dismissed
the complaint for failure to state a claim for relief, concluding the
investors failed to allege with sufficient particularity that KV's
statements were false or misleading. The district court also dismissed the
investors' separate claims for scheme liability against individual KV
officers. Finally, the district court denied the investors' post-judgment
motion to amend their complaint. We affirm in part, reverse in part, and
remand for further proceedings.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The primary issue before us is whether the investors' complaint<a HREF="#fn300" name="fnref_fn300">[fn3]</a> was
sufficient to withstand a motion to dismiss under Rule <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X144L16003?jcsearch=Fed.%20R.%20civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">12</a>(b)(6) of the
Federal Rules of Civil Procedure. Our factual recitation therefore tracks
the allegations in the complaint, which "we are bound to accept as true for
purposes of a Rule 12(b)(6) motion[.]" <i>Joyce v. Armstrong Teasdale, LLP</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F6IEK003?jcsearch=635%20f%203d%20364&amp;summary=yes#jcite">635 F.3d 364</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F6IEK003?jcsearch=635%20f%203d%20364&amp;summary=yes#jcite">365</a> (8th Cir.2011) (internal quotation and punctuation marks
omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  KV is a pharmaceutical company. KV publicly traded securities between June
15, 2004, and January 23, 2009, the "Class Period" alleged in the complaint.
At all relevant times, KV had three operating segments: generic
pharmaceutical products, branded pharmaceutical products, and specialty raw
materials. KV marketed each of its segments through three subsidiary
companies: ETHEX marketed the generic products, Ther-Rx marketed the branded
products, and Particle Dynamics, Inc. marketed the specialty raw materials.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On five occasions during the Class Period (for KV's fiscal years 2004
through 2008), KV filed annual reports with the Securities and Exchange
Commission (SEC) on Form 10-K. The first of the five Form 10-Ks was filed on
June 14, 2004, and the last was filed on June 26, 2008. In the Form 10-Ks,
KV explained in detail the extensive and complex governmental regulation of
the pharmaceutical industry by the FDA. KV then made specific
representations regarding its compliance with <span CLASS="page_no" data-cite="2012 bl 135462 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> FDA regulations. In a section
entitled "Manufacturing And Facilities," KV stated in all five of the
applicable Form 10-Ks: "We believe that all of our facilities are in
material compliance with applicable regulatory requirements." In the 2004
Form 10-K, in a section entitled "Risks Related To Our Industry," KV also
represented:
<span CLASS="page_no" data-cite="679 f 3d 976" data-cite-type="PrimaryFederalReporter" data-cite-pageno="976" data-primary-citation="679 F.3d 972">[*976]</span> 
"We are currently in material compliance with cGMP<a HREF="#fn400" name="fnref_fn400">[fn4]</a> and are registered
with the appropriate state and federal agencies." KV slightly modified this
latter representation in its Form 10-Ks for fiscal years 2005 through 2008
by stating: "We believe that we are currently in material compliance with
cGMP and are registered with the appropriate state and federal agencies."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors' complaint alleges KV's statements regarding its material
compliance with FDA regulations were false or misleading. The investors base
this claim on KVs knowledge of the results of a series of inspections the
FDA made of KVs facilities between 2003 and 2009. The FDA reported the
results of its inspections to KV on Form 483s following inspections which
concluded in April 2003, January 2004, January 2005, March 2006, April 2007,
March 2008, and February 2009. Form 483s are issued pursuant to FDA
regulations to notify a company's "top management in writing of <i>significant</i>
<i>objectionable conditions</i>, relating to products and/or processes, or other
<i>violations</i> of the [FDA] which were observed during the inspection" of a
facility. FDA Investigations Operations Manual, Ch. 5, <cite>&sect; 5.2.3</cite> (2009)
(emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On March 2, 2009, after the last inspection which concluded on February 2,
2009, the United States filed a complaint (the FDA complaint) against KV,
ETHEX, Ther-Rx, and four individual KV officers.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> The government sought
a permanent injunction to prevent KV from manufacturing and distributing
pharmaceuticals due to irregularities in its manufacturing practices. In its
complaint, the FDA stated KV had a "history of continuing . . . violations"
of the FDA's current Good Manufacturing Practices (cGMP). FDA Compl. at &para;
23. The FDA complaint stated the "deficiencies observed by the FDA at the
most recent inspection in February 2009, are the same as, or similar to,
prior violations observed by the FDA at several other inspections during the
last eight years." <i><cite>Id</cite>.</i> The government further alleged KVs "noncompliance has
continued despite repeated warnings from FDA regarding its cGMP violations."
<i></i><cite>Id. at &para; 24</cite> (quoted in the investors' complaint at &para; 8). The FDA complaint
referred to six FDA inspections which took place between April 2003 and
February 2009, in which
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      FDA investigators prepared and issued a detailed List of
    Inspectional Observations, Form FDA-483, to [KV], notifying [KV] of
    the investigator's observations. The FDA investigators discussed the
    violations listed in the Form FDA-483s with [KV], who expressed a
    desire to correct the deficiencies. Nevertheless, FDA investigators
    have continued to observe cGMP violations at subsequent inspections.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i><cite>Id</cite>.</i> (quoted in the investors' complaint at &para; 8).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors' complaint generally alleged KV's manufacturing, processing,
packing, <span CLASS="page_no" data-cite="2012 bl 135462 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> labeling, holding and distribution of drugs were not in compliance
with cGMP, and further alleged the FDA investigators
<span CLASS="page_no" data-cite="679 f 3d 977" data-cite-type="PrimaryFederalReporter" data-cite-pageno="977" data-primary-citation="679 F.3d 972">[*977]</span> 
specifically documented thirty-five separate violations, including:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) Failure to follow the responsibilities and procedures
    applicable to the quality control unit;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (b) Failure to establish control procedures to validate the
    performance of those manufacturing processes that may be responsible
    for causing variability in the characteristics of in-process
    materials and the drug product;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (c) Failure to make written records of investigations into
    unexplained discrepancies and the failure to make written records of
    investigations of a batch or any of its components to meet
    specifications;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (d) Failure to review and approve drug product production and
    control records by the quality control unit to determine compliance
    with all established, approved written procedures before a batch is
    released or distributed;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (e) Failure to review and approve changes to written procedures by
    the quality control unit;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (f) Failure to clean, maintain, and sanitize equipment and
    utensils at appropriate intervals to prevent contamination that
    would alter the safety, identity, strength, quality or purity of the
    drug product; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (g) Failure to follow written production and process control
    procedures in the execution of production and process control
    functions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Investors' Compl. &para; 35.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors alleged KVs manufacturing irregularities resulted in KV
selling adulterated, unapproved, and misbranded drugs in violation of FDA
regulations, and that KV knew since early 2003 it was selling adulterated
and unapproved drugs in violation of FDA regulations. The investors alleged
one of the violations "concerned KVs most important product in 2007 and
2008, Generic Metoprolol, responsible for the supposed explosive growth in
[KVs] revenues and earnings, and sustained high stock prices." <i></i><cite>Id. at &para; 41</cite>.
The investors alleged KVs upper management gave instructions to violate
Quality Control/Quality Assurance (QC/QA) procedures regarding the
manufacture of generic Metoprolol. <i><cite>Id</cite>.</i> The investors alleged the FDA found
evidence that KV did not use the designed process for manufacturing 100mg
tablets of generic Metoprolol during the Class Period between August 5,
2007, and October 17, 2008, by using "an active ingredient that resulted in
smaller particle sizes than approved by FDA in the validation study." <i></i><cite>Id. at
&para; 43</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors further alleged another "flagrant violation" of FDA
regulations involved KVs manufacture of pharmaceutical products which did
not have the correct proportion of ingredients. Instead of discarding the
defective products which were out-of-specification, KVs upper management
decided to "blend" production lots that had low assay values (which refer to
the proportion of ingredients in a product) with production lots that had
high assay values. <i></i><cite>Id. at &para; 44</cite>. In addition, the investors alleged when KV
identified the root cause of the problem during the Class Period on August
6, 2008, it nevertheless failed to correct <span CLASS="page_no" data-cite="2012 bl 135462 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> the problem and continued to
distribute pharmaceutical products using the faulty manufacturing process up
until the FDA's February 2009 inspection. <i>Id.</i>, at &para; 45.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors also alleged KV ignored known and required modifications in
the manufacturing process of Hydromorphone HC1 tablets. "In December 2005
and January 2006, several validation batches `failed to demonstrate control
and reproducibility' because `blend uniformity and potency failures
occurred.'" <i>Id.</i> at &para; 51 (<span CLASS="page_no" data-cite="679 f 3d 978" data-cite-type="PrimaryFederalReporter" data-cite-pageno="978" data-primary-citation="679 F.3d 972">[*978]</span> quoting

from the 2009 Form 483). In other words, KV could not control the exact
dosage in its pharmaceutical products due to deficient manufacturing
processes. KV identified the problem during the Class Period in June 2006
and designed a new production process. Nonetheless, KV then ignored the new
production process and reverted back to the old defective procedures that
had resulted in the manufacture of dangerous drugs. <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors further alleged KV concealed from the FDA the production of
oversized morphine sulfate tablets, which it had discovered during the Class
Period on or about May 15, 2008. KV did not file a field alert with the FDA,
as required, and did not notify the FDA until nearly five months later. At
least two wrongful death lawsuits were filed against KV relating to the
ingestion of oversized morphine sulfate tablets manufactured by KV. <i>Id.</i> at &para;
54(a).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition to the specific violations out-lined above, the investors
alleged a number of other manufacturing irregularities which were noted by
the FDA in the Form 483 from the February 2009 inspection. The investors
attached a copy of the 2009 Form 483 as Exhibit 2 to their complaint. The
2009 Form 483 details a number of manufacturing irregularities which
occurred during the Class Period alleged in the investors' complaint,
including: (a) KVs failure in 2007 to implement adequate corrective and
preventative action in response to over 350 complaints of leaking capsules
of a pharmaceutical product called PrimaCare One; (b) KVs failure to
implement an adequate corrective action in response to several batches of
Histinex HC Syrup packaged with incorrect closures which the FDA identified
in inspections occurring in February 2007 and May 2007; (c) KVs failure to
determine the exact source and nature of metal found in drug products
manufactured between July 22, 2008, and December 25, 2008; (d) KVs conduct
in June 2008 in restocking a lot of Metoprolol tablets initially processed
in August 2007, and then returned without KV investigating the storage
conditions of the product while out of its possession, in order to determine
whether the safety, identity, strength, quality or purity of the tablets had
been destroyed; and (e) KVs conduct, between September 11, 2008, and
November 7, 2008, in using packaging components for six separate products
(including 50mg tablets of Metoprolol) which were disqualified on May 29,
2007.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors' complaint also alleged KVs violations of cGMP and FDA
regulations rendered certain statements KV made about its earnings false and
misleading. In November 2007, <span CLASS="page_no" data-cite="2012 bl 135462 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> KV filed a press release with the SEC on Form
8-K announcing its second quarter fiscal 2008 financial results. Included in
the press release was a statement attributing KVs improvements in net
revenues in large part "to the July 2007 launch of the Company's generic . .
. Metoprolol." In February 2008, KV filed a press release with the SEC on
Form 8-K announcing its third quarter fiscal 2008 financial results. In the
press release, KV attributed a 57.7% increase in revenue from the prior-year
quarter "primarily . . . to sales of 100mg and 200mg strengths of metoprolol
succinate extended release tablets launched in the second quarter of fiscal
2008." In May 2008, KV filed a Form 12b-25 reporting preliminary results for
the fourth quarter fiscal 2008 financial results. KV again attributed its
increase in net revenues "primarily [to] the launch in July 2007 of the
100mg and 200mg strengths of metoprolol succinate extended-release tablets."
Finally, in August 2008, KV filed a press release with the SEC on Form 8-K
reporting its first quarter fiscal 2009 financial results. In the press
release, KV stated "[r]evenue
<span CLASS="page_no" data-cite="679 f 3d 979" data-cite-type="PrimaryFederalReporter" data-cite-pageno="979" data-primary-citation="679 F.3d 972">[*979]</span> 
growth during the quarter was impacted by . . . a net sales gain of 52.6%
over the prior year period at the Company's ETHEX generic/non-branded
marketing subsidiary, contributed to by sales of 25mg, 50mg, 100mg, and
200mg strengths of metoprolol."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors alleged these four statements were false and misleading
because KV knew and failed to disclose that its manufacturing process for
generic Metoprolol violated FDA regulations, including cGMP. More
specifically, the investors' complaint alleged KVs generic Metoprolol: (a)
had not been developed in a scientifically sound manner with appropriate
specifications and process controls; (b) the active pharmaceutical
ingredient used in producing generic Metoprolol was different than the one
used in the design process; and (c) the particle size of post-validation
lots of generic Metoprolol was smaller than the particle sizes used in an
August 5, 2007 validation study. Investors' Compl. &para; 108, 110, 113, 116. The
investors based these three allegations directly on statements the FDA made
in the February 2009 Form 483.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA's supervision of KV eventually affected its stock prices. On
December 23, 2008, KV issued a press release disclosing that, effective
December 19, it had "suspended all shipments of all FDA approved drug
products in tablet form." The price of KVs shares fell from $5.39 to $1.99.
On January 23, 2009, the end of the Class Period alleged in the investors'
complaint, KV completely shut down its manufacturing activities. Three days
later, KV announced it had "suspended the manufacturing and shipment of all
of its products, other than products it distributes but does not
manufacture." KVs stock price dropped to $0.51 per share. The investors
allege they "lost approximately $1.5 billion in market capitalization" from
the collapse in KVs stock price for Class A shares "from more than $30 at
the height of the Class Period, to 51 cents at the close of trading on
January 26, 2009." Investors' Compl. &para; 7.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After <span CLASS="page_no" data-cite="2012 bl 135462 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> the investors filed their complaint, KV filed a motion to dismiss
the complaint for failure to state a claim for relief. The district court
granted the motion to dismiss. The district court determined the statements
KV made in its Form 10-Ks about compliance with FDA manufacturing
regulations were not false or misleading because the forms only listed
"observations" rather than "violations" and were not the FDA's final agency
determination on whether KV was compliant with regulations. The district
court further determined the statements KV made attributing its financial
success to the manufacture and sale of generic Metoprolol were not false or
misleading because the statements were accurate reports of KVs financial
performance, and KV did not have a duty to disclose its manufacturing issues
with generic Metoprolol. The district court also dismissed the claims the
investors brought against the individual KV officers concluding the
investors failed to establish scheme liability. Finally, the district court
denied a post-judgment motion to amend the complaint to supplement the
investors' allegations primarily with information regarding ETHEX's guilty
plea to criminal charges arising from the FDA's investigation. The investors
filed a timely appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors' complaint alleges securities fraud claims brought under
Section 10(b) of the Securities Exchange Act of 1934, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XEHE5S003?jcsearch=15%20U.S.C.%20%2078j(b)&amp;summary=yes#jcite">15 U.S.C. &sect; 78j</a>(b),
and the SEC's <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5&amp;summary=yes#jcite">Rule 10b-5</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20cfr%20240%2010b-5&amp;summary=yes#jcite">17 C.F.R. &sect; 240.10b-5</a>. "<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XEHE5S003?jcsearch=15%20U.S.C.%20%2078j(b)&amp;summary=yes#jcite">Section 10(b)</a> makes it
unlawful `[t]o use or employ, in connection with the purchase or sale of any
security . . . any manipulative or deceptive device or contrivance in
contravention
<span CLASS="page_no" data-cite="679 f 3d 980" data-cite-type="PrimaryFederalReporter" data-cite-pageno="980" data-primary-citation="679 F.3d 972">[*980]</span> 
of such rules and regulations as the [SEC] may prescribe as necessary or
appropriate in the public interest or for the protection of investors.'"
<i>Minneapolis Firefighters' Relief Ass'n v. MEMC Elec. Materials, Inc.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1FJCHG003?jcsearch=641%20f%203d%201023&amp;summary=yes#jcite">641 F.3d 1023</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1FJCHG003?jcsearch=641%20f%203d%201023&amp;summary=yes#jcite">1028</a> (8th Cir.2011) (quoting <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XEHE5S003?jcsearch=15%20U.S.C.%20%2078j(b)&amp;summary=yes#jcite">15 U.S.C. &sect; 78j</a>(b)). Rule 10b-5
implements the provisions of Section 10(b). <i>Matrixx Initiatives, Inc. v.</i>
<i>Siracusano</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20supreme%20court%201309&amp;summary=yes#jcite">131 S.Ct. 1309</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20supreme%20court%201309&amp;summary=yes#jcite">1317</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=179%20l%20ed%202d%20398&amp;summary=yes#jcite">179 L.Ed.2d 398</a> (2011). <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5&amp;summary=yes#jcite">Rule
10b-5</a> makes it unlawful to "make any untrue statement of a material fact or
to omit to state a material fact necessary in order to make the statements
made, in the light of the circumstances under which they were made, not
misleading[.]" <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(b)&amp;summary=yes#jcite">17 C.F.R. &sect; 240.10b-5</a>(b). We employ de novo review to
determine whether the district court properly dismissed the investors'
securities fraud claims. <i>In re NVE Corp. Sec. Litig.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X18VHCM003?jcsearch=527%20f%203d%20749&amp;summary=yes#jcite">527 F.3d 749</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X18VHCM003?jcsearch=527%20f%203d%20749&amp;summary=yes#jcite">751</a> (8th
Cir.2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors first argue the district erred when it determined their
complaint did not allege with sufficient particularity that KV's statements
about material compliance with FDA regulations or cGMP were false or
misleading. The Private Securities Litigation Reform Act of 1995 (PSLRA),
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XEHE7G003?jcsearch=15%20U.S.C.%20%2078u-4(b)(2)&amp;summary=yes#jcite">15 U.S.C. &sect; 78u-4</a>(b)(2), "imposes a heightened pleading standard in cases
alleging securities fraud." <i>Lustgraaf v. Behrens</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1E32DS003?jcsearch=619%20f%203d%20867&amp;summary=yes#jcite">619 F.3d 867</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1E32DS003?jcsearch=619%20f%203d%20867&amp;summary=yes#jcite">873</a> (8th
Cir.2010). The heightened standard requires a plaintiff to "specify each
statement alleged to have been misleading [and] the reason or reasons why
the statement is misleading[.]" <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XEHE7G003?jcsearch=15%20U.S.C.%20%2078u-4(b)(1)&amp;summary=yes#jcite">15 U.S.C. &sect; 78u-4</a>(b)(1). The "circumstances
of the fraud must be stated with particularity, including such matters as
the time, place and contents of false representations, . . . [t]his means
the who, what, when, where, and how." <i>In re <span CLASS="page_no" data-cite="2012 bl 135462 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> K-tel Int'l Inc. Sec. Litig.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X6BI1N?jcsearch=300%20f%203d%20881&amp;summary=yes#jcite">300 F.3d 881</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X6BI1N?jcsearch=300%20f%203d%20881&amp;summary=yes#jcite">890</a> (8th Cir.2002) (internal quotations and citations
omitted). The PSLRA also requires a plaintiff to plead sufficient particular
facts establishing scienter. <i>See</i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XEHE7G003?jcsearch=15%20U.S.C.%20%2078u-4(b)(2)(A)&amp;summary=yes#jcite">15 U.S.C. &sect; 78u-4</a>(b)(2)(A) ("[T]he complaint
shall, with respect to each act or omission alleged to violate this chapter,
state with particularity facts giving rise to a strong inference that the
defendant acted with the required state of mind.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In their complaint, the investors alleged KV made ten specific statements
about its compliance with FDA regulations or cGMP which were false or
misleading. KV made the statements in five annual Form 10-Ks it filed with
the SEC between June 14, 2004, and June 26, 2008. In each Form 10-K, KV
stated "[w]e believe that all of our facilities are in material compliance
with applicable regulatory requirements." In each Form 10-K, KV also stated
"[w]e believe that we are currently in material compliance with cGMP and are
registered with the appropriate state and federal agencies."<a HREF="#fn600" name="fnref_fn600">[fn6]</a> Based on
these specific pleadings, we have no trouble concluding the investors
satisfied the PSLRA's pleading standard with respect to the time, place, and
contents of the allegedly false or misleading representations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The crux is whether the investors' complaint adequately sets forth the
reasons why KVs statements about its material compliance with FDA
regulations or cGMP were false or misleading. The investors rely upon KV's
knowledge of the results of the series of inspections performed by the FDA
before, during, and after the Class Period, which were reported to KV on
Form 483s. The final Form 483 issued by
<span CLASS="page_no" data-cite="679 f 3d 981" data-cite-type="PrimaryFederalReporter" data-cite-pageno="981" data-primary-citation="679 F.3d 972">[*981]</span> 
the FDA following its February 2009 inspection documented thirty-five
separate significant objectionable conditions or other FDA violations which
were observed during the inspection. The investors rely upon the fact that
when the FDA filed its complaint seeking to permanently enjoin KV's
operations, it alleged KV had a history of continuing cGMP violations, and
the violations observed in the February 2009 inspection were "the same as,
or similar to, prior violations observed by FDA at several other inspections
conducted during the last eight years." The investors note the objectionable
conditions observed by the FDA in February 2009 extended back into the Class
Period, and thus contend the February 2009 Form 483 was relevant to the
statements KV made during the Class Period. <i>See, e.g., In re Merck &amp; Co.,</i>
<i>Inc. Sec. Litig.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X13OMGG003?jcsearch=432%20f%203d%20261&amp;summary=yes#jcite">432 F.3d 261</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X13OMGG003?jcsearch=432%20f%203d%20261&amp;summary=yes#jcite">272</a> (3d Cir.2005) ("[B]oth post-class-period
data and pre-class data [can] be used to `confirm what a defendant should
have known during the class period,' [since] `[a]ny information that sheds
light on whether class period statements were false or materially misleading
is relevant.'") (quoting <i>In re Scholastic Corp. Sec. Litig.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X54D69?jcsearch=252%20f%203d%2063&amp;summary=yes#jcite">252 F.3d 63</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X54D69?jcsearch=252%20f%203d%2063&amp;summary=yes#jcite">72</a>
(2d Cir.2001)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In response, KV argues allegations of a company's mere receipt of Form
483s can never satisfy the materiality requirements of a securities fraud
claim because Form 483s simply do not implicate a company's compliant status
with FDA regulations or cGMP, material or otherwise. KV refers to the
explanatory language <span CLASS="page_no" data-cite="2012 bl 135462 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> included on the face of all Form 483 s, which informs
recipients "[t]his document lists observations by the FDA representative(s)
during the inspection of your facility. They are inspectional observations,
and do not represent final Agency determination regarding your compliance."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We reject KV's contention that the receipt of Form 483s can never render a
company's statements about compliance with FDA regulations or cGMP false or
misleading. The "fundamental purpose" of the Securities Exchange Act is to
"implement[] a philosophy of full disclosure" in order "to protect investors
against manipulation of stock prices." <i>Basic Inc. v. Levinson</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2N742?jcsearch=485%20us%20224&amp;summary=yes#jcite">485 U.S. 224</a>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2N742?jcsearch=485%20us%20224&amp;summary=yes#jcite">230</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/1?citation=108%20supreme%20court%20978&amp;summary=yes#jcite">108 S.Ct. 978</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2N742?jcsearch=99%20l%20ed%202d%20194&amp;summary=yes#jcite">99 L.Ed.2d 194</a> (1988) (internal quotation marks and
citations omitted). To accomplish that purpose, the Supreme Court has
"explicitly . . . defined a standard of materiality" to determine when a
statement or omission would be considered false or materially misleading by
a reasonable investor. <i>Id.</i> at 231, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/1?citation=108%20supreme%20court%20978&amp;summary=yes#jcite">108 S.Ct. 978</a>. "To fulfill the
materiality requirement there must be a substantial likelihood that the
disclosure of the omitted fact would have been viewed by the reasonable
investor as having significantly altered the total mix of information made
available." <i>Detroit Gen. Ret Sys. v. Medtronic, Inc.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1E65IE003?jcsearch=621%20f%203d%20800&amp;summary=yes#jcite">621 F.3d 800</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1E65IE003?jcsearch=621%20f%203d%20800&amp;summary=yes#jcite">805</a> (8th
Cir.2010) (internal quotation marks and citation omitted). Under the
circumstances present in this case, we conclude there is a substantial
likelihood KVs disclosure of its receipt of Form 483 s, during the same time
period it was representing it was in material compliance with FDA
regulations and cGMP, would have been viewed by the reasonable investor as
having significantly altered the total mix of information made available.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our rejection of KV's per se rule, holding a company's receipt of Form
483s never renders statements about material compliance with FDA regulations
or cGMP false or misleading, is consistent with a number of district court
decisions which have recognized the materiality of a company's receipt of
Form 483s. <i>See McGuire v. Dendreon Corp.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1Q6L5H4GE82?jcsearch=688%20f%20supp%202d%201239&amp;summary=yes#jcite">688 F.Supp.2d 1239</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1Q6L5H4GE82?jcsearch=688%20f%20supp%202d%201239&amp;summary=yes#jcite">1241</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1Q6L5H4GE82?jcsearch=688%20f%20supp%202d%201239&amp;summary=yes#jcite">1244-45</a>
(W.D.Wash. 2009) (<i>Dendreon II</i>) (granting leave to amend a complaint, where a
defendant stated his company had "hosted a good inspection"
<span CLASS="page_no" data-cite="679 f 3d 982" data-cite-type="PrimaryFederalReporter" data-cite-pageno="982" data-primary-citation="679 F.3d 972">[*982]</span> 
at a manufacturing plant without revealing the fact that the FDA issued a
Form 483 following the inspection, concluding "the existence of the Form 483
might well have led his audience to conclude it was <i>not</i> a good inspection");
<i>Yanek v. Staar Surgical Co.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XKBFDVQNB5G0?jcsearch=388%20f%20supp%202d%201110&amp;summary=yes#jcite">388 F.Supp.2d 1110</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XKBFDVQNB5G0?jcsearch=388%20f%20supp%202d%201110&amp;summary=yes#jcite">1129</a> (C.D.Cal.2005)
(finding the FDA's issuance of a Form 483 material to a company's statements
about the timing of FDA approval of an implantable contact lenses (ICL)
because issuance of the Form 483 was a "fact[] bearing on possible delays in
FDA approval of the ICL"); <i>Wilkof v. Caraco Pharm. Labs, Ltd.</i>, No. <cite>09-12830</cite>,
<cite>2010 WL 4184465</cite>, at *6 (E.D.Mich. Oct. 21, 2010) (denying a motion to
dismiss in a case where a company represented it was "substantially cGMP
compliant" contemporaneously with receiving Form 483s noting serious
manufacturing problems, including tablet size variation, failures to
thoroughly investigate, and the company's general "inability to produce
quality pills, <i>i.e.</i>, drug products that have the identity, strength,
quality, and <span CLASS="page_no" data-cite="2012 bl 135462 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> purity they purport or are represented to possess"); <i>In re Able</i>
<i>Labs. Sec. Litig.</i>, No. <cite>05-2681</cite>, [<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X18N3QM003?jcsearch=2008%20BL%2067246&amp;summary=yes#jcite">2008 BL 67246</a>], 2008 WL 1967509, at *16, 30 (D.N.J. March
24, 2008) (denying a motion to dismiss in a case involving a company's
receipt of an FDA warning letter and Form 483 where the defendants
represented the company was compliant with cGMP and all applicable FDA
requirements); <i>In re Cryolife, Inc.</i>, No. <cite>Civ.A.1:02CV1868-BBM</cite>,
<cite>2003 WL 24015055</cite>, at *8 (N.D.Ga. May 27, 2003) (denying a motion to dismiss
in a case involving a company's receipt of a Form 483 noting twelve specific
observations of regulatory violations at the same time it represented it in
was "in compliance with all FDA regulations").<a HREF="#fn700" name="fnref_fn700">[fn7]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The issuance of a Form 483 represents a risk that the FDA may take
corrective action against a company, and thus a company is obligated to
assess the seriousness of the risk and disclose such information to
potential investors if it also represents it is in compliance with FDA
regulations and cGMP. <i>See Gebhardt v. ConAgra Foods, Inc.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2LF9A?jcsearch=335%20f%203d%20824&amp;summary=yes#jcite">335 F.3d 824</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2LF9A?jcsearch=335%20f%203d%20824&amp;summary=yes#jcite">831</a>
(8th Cir.2003) ("We keep in the forefront of our minds [the] fact that
`[j]ust because a hidden risk does not materialize doesn't mean its
concealment cannot hurt investors.'") (quoting <i>Rodney v. KPMG Peat Marwick</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X4805V?jcsearch=143%20f%203d%201140&amp;summary=yes#jcite">143 F.3d 1140</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X4805V?jcsearch=143%20f%203d%201140&amp;summary=yes#jcite">1144</a> (8th Cir.1998)); <i>see also In re SFBC Intern., Inc. Sec.</i>
<i>&amp; Derivative Litig.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X17CD3Q003?jcsearch=495%20f%20supp%202d%20477&amp;summary=yes#jcite">495 F.Supp.2d 477</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X17CD3Q003?jcsearch=495%20f%20supp%202d%20477&amp;summary=yes#jcite">481</a> n. 2 (D.N.J.2007) ("While the
observations contained in a Form 483 report do not constitute a final agency
determination regarding the facility's compliance with applicable laws and
regulations, corrective action by the inspected company is expected.");
<i>McGuire v. Dendreon Corp.</i>, No. C07-800MJP, 2008 WL 5130042, at *6 (W.D.Wash.
Dec. 5, 2008) (<i>Dendreon I</i>) ("One need not know the contents of an
unfavorable report (a fair characterization of the Form 483 under the best
of circumstances) to state with a high degree of certainty that the mere
fact of its existence would have a negative impact on the hopes and
expectations of investors, and thus upon the value of the stock.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  From our review of the caselaw we glean the following principle: for
purposes of pleading a securities fraud claim, the issuance of Form 483s may
render a defendant's statement about its compliance
<span CLASS="page_no" data-cite="679 f 3d 983" data-cite-type="PrimaryFederalReporter" data-cite-pageno="983" data-primary-citation="679 F.3d 972">[*983]</span> 
with FDA regulations or cGMP false, or at least misleading, in some
circumstances. The FDA's issuance of Form 483s may be material depending on
a number of factors, including the number, severity, and pervasiveness of
objectionable conditions noted, as well as whether a company has failed to
address or correct the deficiencies noted by the FDA. There is a substantial
likelihood the presence of these factors would be viewed by a reasonable
investor as significantly altering the total mix of information made
available, irrespective of whether the Form 483 represents the FDA's final
say on compliance issues.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this case, the investors' complaint pleads numerous, severe, and
pervasive objectionable conditions which were outlined in the Form 483s. The
investors alleged there was a lengthy history of KV manufacturing
adulterated, unapproved, and misbranded drugs in violation of FDA
regulations due to manufacturing irregularities. The manufacturing
irregularities included KV's failure to manufacture pharmaceutical products
with <span CLASS="page_no" data-cite="2012 bl 135462 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> the correct proportion of ingredients, and the correct tablet sizes,
during the Class Period. The investors also alleged KV failed to address or
correct serious manufacturing problems during the Class Period (including
the failure to investigate metal particles found in four different products,
and the development of new design processes to correct problems but then a
failure to implement them), incorporating the allegations in the FDA's March
2009 complaint which indicated KV's "noncompliance has continued despite
repeated warnings from FDA regarding its cGMP violations." Finally, the
investors' complaint indicates KVs operations were ultimately shut down as a
result of its failure to comply with the FDA's requirements, and the stock
market reacted to news of the shutdown with a significant drop in the price
of KV's stock. <i>See Medtronic</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1E65IE003?jcsearch=621%20f%203d%20800&amp;summary=yes#jcite">621 F.3d at 807</a> ("A significant change in
stock price upon disclosure of withheld information is strong evidence that
the information was material.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under this set of facts,<a HREF="#fn900" name="fnref_fn900">[fn9]</a> we conclude the investors' complaint
adequately set forth
<span CLASS="page_no" data-cite="679 f 3d 984" data-cite-type="PrimaryFederalReporter" data-cite-pageno="984" data-primary-citation="679 F.3d 972">[*984]</span> 
the reasons why KV's statements about its compliance with FDA regulations
and cGMP were false, or at least misleading, at the time they were made.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors next argue the district court erred when it determined they
did not sufficiently plead that KV made false or misleading statements about
earnings tied to the manufacture of generic Metoprolol. The investors
contend KV had a duty to disclose the manufacturing problems associated with
generic Metoprolol because KV chose to publicly highlight the product's
financial success. Although KV accurately reported its past financial
figures, the investors claim the statements were nevertheless misleading
because KV omitted the material fact that it could not manufacture generic
Metoprolol within approved FDA guidelines and was violating cGMP in its
production of generic Metoprolol.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court held KV did not have a duty to disclose its
manufacturing problems with generic Metoprolol because
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      KV did not attribute its financial success to its outstanding
    manufacturing processes or quality control measures associated with
    the production of the generic metoprolol. Moreover, the financial
    statements did not discuss KV compliance with the FDA regulations.
    Because KV chose only to speak about the financial status of the
    company, KV was not required to dump all known information about its
    manufacturing and regulatory issues.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Pub. Pension Fund Grp. v. KV Pharm. Co.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1CJ1J8003?jcsearch=705%20f%20supp%202d%201088&amp;summary=yes#jcite">705 F.Supp.2d 1088</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1CJ1J8003?jcsearch=705%20f%20supp%202d%201088&amp;summary=yes#jcite">1102</a> (E.D.Mo.
2010) (internal quotation marks omitted). We agree with the district court.
KV did not undertake a duty to speak about its manufacturing problems with
generic Metoprolol solely by reporting historical financial results.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Silence, absent a duty to disclose, is not misleading under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5&amp;summary=yes#jcite">Rule 10b-5</a>."
<i>Basic Inc.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2N742?jcsearch=485%20us%20224&amp;summary=yes#jcite">485 U.S. at 239</a> n. 17, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/1?citation=108%20supreme%20court%20978&amp;summary=yes#jcite">108 S.Ct. 978</a>. Even assuming KV's
manufacturing problems with generic Metoprolol were material, "[M]ateriality
alone is not sufficient to place a company under a duty of disclosure."
<i>K-tel</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X6BI1N?jcsearch=300%20f%203d%20881&amp;summary=yes#jcite">300 F.3d at 898</a> (citation omitted). In the statements at issue, <span CLASS="page_no" data-cite="2012 bl 135462 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> KV
only reported past financial performance. The financial statements did not
discuss compliance with FDA regulations, or tie KV's financial performance
directly to manufacturing processes. As a result, KV's statements did not
trigger a duty to disclose its compliance with FDA regulations, or to
discuss its manufacturing problems with generic Metoprolol. While <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5&amp;summary=yes#jcite">Rule 10b-5</a>
requires "an actor to provide complete and non-misleading information with
respect to the subjects <i>on which he under-takes to speak</i> . . . the
requirement is not to dump all known information with every public
announcement[.]" <i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5&amp;summary=yes#jcite">Id</a>.</i> (internal quotations and citation omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The primary case cited by the investors, <i>In re Gilead Sciences Securities</i>
<i>Litigation</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X19DG64003?jcsearch=536%20f%203d%201049&amp;summary=yes#jcite">536 F.3d 1049</a> (9th Cir.2008), does not support their argument
that KV had a duty to disclose the manufacturing problems associated with
generic Metoprolol. The investors contend <i>Gilead</i> held a company's failure to
disclose its off-label sale of a pharmaceutical product, contrary to FDA
regulations, "was actionable because Gilead chose to tout the drug as a
primary driver of its earnings." Appellants' Br. at 49. The investors rely
upon the following quote from <i>Gilead</i>:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Gilead issued a press release announcing that it anticipated its
    second quarter financial results would exceed analysts'
    expectations, and explaining that the
<span CLASS="page_no" data-cite="679 f 3d 985" data-cite-type="PrimaryFederalReporter" data-cite-pageno="985" data-primary-citation="679 F.3d 972">[*985]</span> 
    company's success "was driven primarily by strong sales growth of
    Viread Increasing Viread sales reflect broader prescribing patterns
    in all commercial markets, as well as increases in U.S. wholesaler
    inventory levels in the second quarter in anticipation of a Viread
    price increase."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      These statements were materially false and misleading because
    Gilead and its Officers `"marketing and promotional activities for
    Viread were not in compliance with FDA approved guidelines, violated
    federal laws, and created serious public health and safety
    implications for Viread users."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Gilead</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X19DG64003?jcsearch=536%20f%203d%201049&amp;summary=yes#jcite">536 F.3d at 1052</a>. The above quote appears in the portion of the
opinion where the Ninth Circuit merely summarized the allegations in the
plaintiffs' complaint, however, and does not represent the court's holding.
Indeed, <i>Gilead</i> did not even address whether a statement was misleading due
to a duty to disclose, but rather dealt with the issue of loss causation.
<i>See </i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X19DG64003?jcsearch=536%20F.3d%201049&amp;summary=yes#jcite">id. at 1056-58</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors also rely upon the Supreme Court's recent decision in
<i>Matrixx</i>, contending it stands for the broad proposition that a statement
ascribing past financial success to a particular product is misleading
unless the problems associated with the product are also disclosed. We
disagree. <i>Matrixx</i> involved the cold remedy, Zicam, which allegedly accounted
for 70% of Matrixx's sales. <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20S.Ct.%201309&amp;summary=yes#jcite">131 S.Ct. at 1323</a>. Matrixx made public
statements attributing a sizeable net sales increase to Zicam, and
projecting future growth of the company due to the sale of Zicam. <i>See</i>
<i>Siracusano v. Matrixx Initiatives, Inc.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1C1OJC003?jcsearch=585%20f%203d%201167&amp;summary=yes#jcite">585 F.3d 1167</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1C1OJC003?jcsearch=585%20f%203d%201167&amp;summary=yes#jcite">1181</a> (9th Cir.2009).
The Supreme Court held the plaintiffs stated an actionable claim by pleading
that Matrixx failed to disclose reports of a possible link between Zicam and
loss of the sense of <span CLASS="page_no" data-cite="2012 bl 135462 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> smell (anosmia). <i>Matrixx</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20S.Ct.%201309&amp;summary=yes#jcite">131 S.Ct. at 1323</a>.
Significantly, however, the misleading statements upon which the Supreme
Court focused were not the reports of past financial success attributing
earnings to the sale of Zicam. Rather, the statements the Supreme Court held
actionable were those in which Matrixx "stated that reports indicating that
Zicam caused anosmia were `completely unfounded and misleading' and that
`the safety and efficacy of zinc gluconate for the treatment of symptoms
related to the common cold have been well established.'" <i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20S.Ct.%201309&amp;summary=yes#jcite">Id</a>.</i> Matrixx made
these statements while at the same time projecting future growth in the sale
of Zicam. <i>See <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20S.Ct.%201309&amp;summary=yes#jcite">id</a>.</i> ("Matrixx told the market that revenues were going to rise
50 and then 80 percent.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, in <i>Matrixx</i> there was a direct connection between the information the
company failed to disclose &mdash; the adverse reports of a link between the use
of Zicam and anosmia &mdash; and the public statements the company made indicating
the reports that Zicam causes anosmia were completely unfounded and
misleading. In addition, the company made statements projecting future
growth attributable to the product in issue. This case is distinguishable.
KVs statements were accurate reports of its past financial success, and
there was no direct connection between those statements and the alleged
manufacturing problems associated with generic Metoprolol. In addition, the
investors do not allege KV misled investors with projections regarding
future performance, as KV only undertook to speak about its past financial
success. We therefore conclude the district court did not err when it
determined the investors' complaint did not sufficiently plead that KV made
false or misleading statements about earnings tied to the manufacture of
generic Metoprolol.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors next contend the district court improperly dismissed their
claims
<span CLASS="page_no" data-cite="679 f 3d 986" data-cite-type="PrimaryFederalReporter" data-cite-pageno="986" data-primary-citation="679 F.3d 972">[*986]</span> 
brought pursuant to <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rules 10b-5(a)</a> and <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a> against two individual KV
officers: David A. Van Vliet, KVs Chief Administrative Officer from
September 2006 until September 2008, the President and CEO of ETHEX from
September 2008 until December 5, 2008, and KVs Corporate President and
interim CEO after December 5, 2008; and Rita E. Bleser, the President of KVs
Pharmaceutical Manufacturing Division since April 2007. <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rule 10b-5(a)</a>
prohibits "any device, scheme or artifice to defraud."
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">17 C.F.R. &sect; 240.10b-5</a>(a). <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">Rule 10b-5(c)</a> prohibits "any act, practice, or
course of business which operates or would operate as a fraud or deceit upon
any person[.]" <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">17 C.F.R. &sect; 240.10b-5</a>(c). Claims brought under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rules 10b-5(a)</a>
and <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a> are generally referred to as "scheme liability" claims. <i>See, e.g.,</i>
<i>In re DVI, Inc. Sec. Litig.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F6JH8003?jcsearch=639%20f%203d%20623&amp;summary=yes#jcite">639 F.3d 623</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F6JH8003?jcsearch=639%20f%203d%20623&amp;summary=yes#jcite">643</a> n. 29 (3d Cir.2011) ("We
refer to claims under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rule 10b-5(a)</a> and <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a> as `scheme liability claims'
because they make deceptive conduct actionable, as opposed to <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(b)&amp;summary=yes#jcite">Rule 10b-5(b)</a>,
which relates to deceptive statements.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors generally alleged Van Vliet and Bleser "carried out a plan,
scheme, and course of conduct which was intended to and, throughout the
Class Period, did . . . deceive the investing public . . . and . . . caused
. . . members of the Class to purchase KV securities at artificially
inflated prices." Investors' Compl. &para; 163. To support this general
allegation, <span CLASS="page_no" data-cite="2012 bl 135462 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> the investors incorporated their allegations regarding the false
and misleading statements about KVs compliance with FDA regulations and
cGMP, and the allegations regarding the false and misleading statements
about earnings tied to the production of generic Metoprolol, and then
alleged Van Vliet and Bleser "had actual knowledge of the misrepresentations
and omissions of material fact as set forth herein." <i></i><cite>Id. at &para; 167</cite>. Other
than incorporating the allegations regarding the mis-representations and
omissions, the investors only generally alleged Van Vliet and Bleser
"employed devices, schemes, and artifices to defraud[,] engaged and
participated in a continuous course of conduct to conceal adverse material
information about the business [and] engaged in transactions, practices and
a course of conduct that operated as a fraud and deceit upon the purchasers
of KV securities." <i>Id.</i> at &para; 164-66.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Based upon these allegations, the district court dismissed the scheme
liability claims against Van Vliet and Bleser because the "plaintiffs fail
to allege with sufficient particularity how the scheme operated and how Van
Vliet and Bleser were actually involved. As such, the Court finds that lead
plaintiffs' conclusory allegations fail to state claims under Rule 10b-5(a)
and (c) against Van Vliet and Bleser." <i>KV Pkarm.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1CJ1J8003?jcsearch=705%20f%20supp%202d%201088&amp;summary=yes#jcite">705 F.Supp.2d at 1106</a>. We
agree with the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The investors' conclusory allegations regarding Van Vliet and Bleser
employing devices, schemes, and artifices to defraud do not satisfy the
requirements of pleading fraud under Rule <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X144L10003?jcsearch=Fed.%20r.%20civ.%20p.%209(b)&amp;summary=yes#jcite">9</a>(b) of the Federal Rules of Civil
Procedure. <i>See, e.g., In re Parmalat Sec. Litig.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XKBO7JQNB5G0?jcsearch=414%20f%20supp%202d%20428&amp;summary=yes#jcite">414 F.Supp.2d 428</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XKBO7JQNB5G0?jcsearch=414%20f%20supp%202d%20428&amp;summary=yes#jcite">432</a>
(S.D.N.Y.2006) ("Although the heightened pleading requirements of the PSLRA
do not apply to claims under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rule 10b-5(a)</a> and <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a>, such claims must be
pleaded with specificity under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X144L10003?jcsearch=Fed.%20r.%20civ.%20p.%209(b)&amp;summary=yes#jcite">Rule 9(b)</a>. Accordingly, a plaintiff . . .
must specify, with particularity, what manipulative acts were performed,
which defendants performed them, when the manipulative acts were performed
and what effect the scheme had on the securities at issue.") (internal
quotation marks and citations omitted). The investors do not allege what
specific manipulative acts either Van Vliet or Bleser performed, or when the
manipulative acts were performed.
<span CLASS="page_no" data-cite="679 f 3d 987" data-cite-type="PrimaryFederalReporter" data-cite-pageno="987" data-primary-citation="679 F.3d 972">[*987]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The only scheme liability allegations in the investors' complaint which
arguably are <i>not</i> merely conclusory are those which incorporate the
allegations regarding the misrepresentations or omissions about FDA/cGMP
compliance, and earnings tied to generic Metoprolol. The investors allege
Van Vliet and Bleser had knowledge of those misrepresentations or omissions.
The district court held, however, that mis-representation claims under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(b)&amp;summary=yes#jcite">Rule
10b-5(b)</a> cannot simply be recast as scheme liability claims under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rules
10b-5(a)</a> and <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a> unless a plaintiff alleges a defendant "participated in a
scheme that encompassed conduct beyond misrepresentation." <i>KV Pharm.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1CJ1J8003?jcsearch=705%20f%20supp%202d%201088&amp;summary=yes#jcite">705 F.Supp.2d at 1104</a> (quoting <i>In re Alstom SA Sec. Litig.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XKBM3RQNB5G0?jcsearch=406%20f%20supp%202d%20433&amp;summary=yes#jcite">406 F.Supp.2d 433</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XKBM3RQNB5G0?jcsearch=406%20f%20supp%202d%20433&amp;summary=yes#jcite">475</a> (S.D.N.Y.2005)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have not directly addressed this issue in our circuit, but "the two
circuit courts that traditionally see the most securities cases [are] the
Second and Ninth Circuits." Nicholas Fortune <span CLASS="page_no" data-cite="2012 bl 135462 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> Schanbaum, <i>Scheme Liability:</i>
<i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rule 10b-5(a)</a> and Secondary Actor Liability after Central Bank</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/1?citation=26%20Rev.%20Litig.%20183&amp;summary=yes#jcite">26 Rev.
Litig. 183</a>, 197 (Winter 2007). Both the Second and the Ninth Circuits have
held "[a] defendant may only be liable as part of a fraudulent scheme based
upon misrepresentations and omissions under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rules 10b-5(a)</a> or <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a> when the
scheme also encompasses conduct beyond those misrepresentations or
omissions." <i>WPP Luxembourg Gamma Three Sari v. Spot Runner, Inc.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1G48LS003?jcsearch=655%20f%203d%201039&amp;summary=yes#jcite">655 F.3d 1039</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1G48LS003?jcsearch=655%20f%203d%201039&amp;summary=yes#jcite">1057</a> (9th Cir.2Qll); <i>Lentell v. Merrill Lynch &amp; Co.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XGKE4M?jcsearch=396%20f%203d%20161&amp;summary=yes#jcite">396 F.3d 161</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XGKE4M?jcsearch=396%20f%203d%20161&amp;summary=yes#jcite">177</a> (2d Cir.2005) ("[W]here the sole basis for such claims is
alleged misrepresentations or omissions, plaintiffs have not made out a
market manipulation claim under <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(a)&amp;summary=yes#jcite">Rule 10b-5(a)</a> and <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(c)&amp;summary=yes#jcite">(c)</a>[.]"). We join the
Second and Ninth Circuits in recognizing a scheme liability claim must be
based on conduct beyond misrepresentations or omissions actionable under
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/XMIE6Q003?jcsearch=17%20C.F.R.%20%20240.10b-5(b)&amp;summary=yes#jcite">Rule 10b-5(b)</a>. Because the investors do not allege with specificity (or
otherwise) what conduct Van Vliet and Bleser engaged in beyond having
knowledge of the misrepresentations and omissions regarding FDA/cGMP
compliance and earnings tied to generic Metoprolol, the district court
correctly dismissed the scheme liability claims against the two individual
KV officers.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  D
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the investors contend the district court erred when it denied
their post-judgment motion to amend the complaint. Because the motion to
amend was filed post-judgment, we review the district court's decision for
an abuse of discretion, keeping in mind the district court was not at
liberty to "ignore the Rule 15(a)(2) considerations that favor affording
parties an opportunity to test their claim on the merits[.]" <i>United States</i>
<i>ex rel. Roop v. Hypoguard USA Inc.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1AP0O6003?jcsearch=559%20f%203d%20818&amp;summary=yes#jcite">559 F.3d 818</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1AP0O6003?jcsearch=559%20f%203d%20818&amp;summary=yes#jcite">824</a> (8th Cir.2009).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, the investors focus on two aspects of their proposed amended
complaint. First, the proposed amended complaint alleged KV engaged in a
criminal cover-up of its manufacturing problems starting in May 2008. The
cover-up ultimately resulted in ETHEX pleading guilty in February 2010 to
two felony counts of fraud "as a result of failing to report [to the FDA]
the discovery of tablets that did not meet product specifications."
Investors' Second Amended Compl. (SAC) &para; 104. As part of the guilty plea,
ETHEX agreed to pay $27 million in fines, restitution, and administrative
forfeitures. Referring to the criminal information filed by the United
States against ETHEX, the investors alleged the guilty plea resulted from
two specific instances in May 2008 in which KV received reports of oversized
morphine tablets from pharmacies. KV investigated the problem in May and
June 2008 and discovered the problem was not limited to
<span CLASS="page_no" data-cite="679 f 3d 988" data-cite-type="PrimaryFederalReporter" data-cite-pageno="988" data-primary-citation="679 F.3d 972">[*988]</span> 
morphine tablets, but extended to additional products including Propanefone
(an anti-arrhythmic drug used to treat heart disease) and dextroamphetamine
sulfate (a drug marketed for use primarily by children to treat attention
deficit hyperactive disorder). KV reported the discovery of the oversized
morphine tablets to the FDA "more than a month late," which itself "violated
FDA regulations," but more "[c]ritically, KV did not reference the
discovery, of other oversized tablets." <i></i><cite>Id. at &para; 112</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition, a KV officer identified <span CLASS="page_no" data-cite="2012 bl 135462 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> as "Corporate Executive A" in the
criminal information directed the cover-up by choosing to "do nothing" in
response to the problem and instructing "multiple KV employees to minimize
written communications about KVs oversized tablet manufacturing problems,
and limit distribution and discussion of any documents discussing these
problems given the `business risk' created by written materials." <i></i><cite>Id. at &para;
115</cite>. The investors alleged Marc Hermelin, one of the individual defendants
in this case, was "Corporate Executive A" because Hermelin was subsequently
"dismissed for cause," and "Hermelin's dismissal was a result of the Audit
Committee's investigation into FDA regulatory compliance and management
misconduct." <i>Id.</i> at &para; 113, 149.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition to alleging that this conduct violated FDA regulations (which
would support the original complaint's allegation that the Form 10-K which
KV filed on June 26, 2008, was false and misleading because it represented
KV was FDA compliant), the proposed amended complaint alleged KV made an
additional false statement. The investors alleged on August 11, 2008 (during
the Class Period), KV filed a Form 10-Q with the SEC which stated:
"Management is not aware of and does not believe that there has been any
misconduct that would have a material impact on the Company's financial
results." <i>Id.</i> at &para; 147. The investors alleged this statement was false and
misleading since KV (and Hermelin) knew the cover-up could have a material
impact on KVs financial results because "the misconduct concerned over-dosed
tablets of multiple drugs, additional recalls, and `business risk.'" <i>Id.</i> at
&para; 148(b).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, the proposed amended complaint included an expert report from a
former FDA inspector who opined that the issuance of the Form 483s meant KV
was not in compliance with cGMP. In their memorandum of law in support of
the motion to amend, the investors argued the expert report "cure[d] the
deficiencies set forth" in the district court's order dismissing the
original complaint, referring to the fact that the order "was largely based
on the Court's finding that `the Form 483s issued to KV only contained
observations &mdash; not a list of cGMP violations as alleged by lead
plaintiffs.'" App. at 839 (quoting the district court's order). The
investors argued the former FDA inspector's report established that the use
of the term "observation" was interchangeable with the use of the term
"violation." <i>Id.</i> at 839-40.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court denied the motion to amend for several reasons. First,
it stated ETHEX's guilty plea merely added evidentiary support to the
original allegations which the district court had determined
<span CLASS="page_no" data-cite="679 f 3d 989" data-cite-type="PrimaryFederalReporter" data-cite-pageno="989" data-primary-citation="679 F.3d 972">[*989]</span> 
were insufficient to state a cause of action. Second, the district court
noted the coverup conduct took place after May 2008, and therefore covered
only a small portion of the relevant class period. Finally, the district
court said there was nothing about the guilty plea that mentioned individual
defendants to this action. The district court did not specifically address
the expert report from a former FDA inspector in denying the motion to
dismiss.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, the investors argue <span CLASS="page_no" data-cite="2012 bl 135462 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[**16]</span> the district court erred in denying the
motion to amend the complaint because ETHEX's guilty plea established felony
violations of FDA regulations beginning in May 2008. The investors argue the
new allegations regarding the guilty plea would have compelled the district
court to view the criminal behavior as an undeniable violation of FDA
regulations, not merely an observation. The investors contend their new
allegations established a viable class period of at least May 2008 through
January 2009, and that KV's August 2008 statement declaring its ignorance of
material misconduct was false when made.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, the investors argue the district court erred when it said the SAC
did not mention individual defendants to this action, because the SAC
specifically mentioned Hermelin and alleged he was the "Corporate Executive
A" referred to in the criminal charges against ETHEX. On appeal, the
investors note Hermelin's subsequent guilty plea to misbranding drugs
confirms he was "Corporate Executive A."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the investors argue the district court erred when it denied the
motion to amend the complaint on the grounds that the SAC merely added
evidentiary support to the original allegations, pointing out the district
court dismissed the original allegations precisely for lack of sufficient
evidentiary support.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We conclude the district court abused its discretion in denying the motion
to amend the complaint. The new allegations supported the investors'
contention that KV made false and misleading statements during the Class
Feriod, and we are unaware of any legal basis for discounting this relevant
information simply because it covers only a portion of the relevant Class
Period. <i>See In re Scholastic Corp.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X54D69?jcsearch=252%20f%203d%2063&amp;summary=yes#jcite">252 F.3d at 72</a> ("Any information that
sheds light on whether class period statements were false or materially
misleading is relevant.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition, the SAC added allegations regarding a new statement KV made
on August 11, 2008. The criminal behavior alleged in the SAC was relevant to
determining whether this new statement was actionable in its own right,
irrespective of whether the original allegations were insufficient. Yet, the
district court never addressed this issue before denying the motion to
amend.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also relied upon an improper factor when it stated the
guilty plea did not involve any individual defendants to this action. <i>See</i>
<i>Dunn v. Nexgrill Indus., Inc.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F13KG003?jcsearch=636%20f%203d%201049&amp;summary=yes#jcite">636 F.3d 1049</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F13KG003?jcsearch=636%20f%203d%201049&amp;summary=yes#jcite">1055</a> (8th Cir.2011)
(indicating a "district court abuses its discretion when it . . . considers
and gives significant weight to an irrelevant or improper factor"). The SAC
specifically mentioned Hermelin and specifically alleged he was the
"Corporate Executive A" referred to in ETHEX's criminal charges. The
allegations in the SAC were already sufficient to create the inference that
Hermelin was "Corporate Executive A," but even if they were not, Hermelin's
subsequent guilty plea confirmed the SAC's allegations.
<span CLASS="page_no" data-cite="679 f 3d 990" data-cite-type="PrimaryFederalReporter" data-cite-pageno="990" data-primary-citation="679 F.3d 972">[*990]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Given our preference for "affording parties an opportunity to test their
claim on the merits," <i>Roop</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1AP0O6003?jcsearch=559%20f%203d%20818&amp;summary=yes#jcite">559 F.3d at 824</a>, as well as our determination
<span CLASS="page_no" data-cite="2012 bl 135462 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[**17]</span> that some of the allegations in the original complaint already sufficiently
pleaded the false or misleading nature of statements KV made during the
Class Period, we direct the district court on remand to grant the investors'
motion to amend their complaint.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the reasons stated, we affirm in part, reverse in part, and remand to
the district court for further proceedings consistent with this opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The Norfolk County Retirement System and the State-Boston Retirement
System were appointed by the court as the lead plaintiffs in this class
action on behalf of all investors. Hereinafter we will refer to all the
plaintiffs collectively as "the investors."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> We grant the motions brought by both sides to file surreply briefs
addressing the Supreme Court's recent decision in <i>Matrixx Initiatives, Inc.</i>
<i>v. Siracusano</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=131%20supreme%20court%201309&amp;summary=yes#jcite">131 S.Ct. 1309</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1F576K003?jcsearch=179%20l%20ed%202d%20398&amp;summary=yes#jcite">179 L.Ed.2d 398</a> (2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Unless otherwise indicated, references to the "investors' complaint"
refer to the Consolidated Amended Complaint dated May 22, 2009.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Current Good Manufacturing Practices.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> Three of the four individual KV officers sued by the United States are
also individual defendants in this case: Marc S. Hermelin, KV's Chairman and
Chief Executive Officer (CEO) at all relevant times until his termination
for cause on December 5, 2008; David A. Van Vliet, who served as KV's Chief
Administration Officer from September 2006 until September 2008, as the
President and CEO of ETHEX from September 2008 until December 5, 2008, and
as KV's Corporate President and interim CEO after Hermelin was fired for
cause on December 5, 2008; and Rita E. Bleser, the President of KV's
Pharmaceutical Manufacturing Division since April 2007.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> As noted above, KV not only represented its <i>belief</i> that it was in
material compliance in the 2004 Form 10-K, but affirmatively stated "[w]e
are currently in material compliance with cGMP and are registered with the
appropriate state and federal agencies."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> We are not persuaded by KV's reliance on <i>Acito v. IMCERA Group, Inc.</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NJ6V?jcsearch=47%20f%203d%2047&amp;summary=yes#jcite">47 F.3d 47</a> (2d Cir.1995), which held a company was not obligated to disclose
the results of unfavorable FDA inspections to the investing public. <i></i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NJ6V?jcsearch=47%20F.3d%2047&amp;summary=yes#jcite">Id. at
52</a>. <i>Acito</i> did not involve allegations by investors that a company made false
or misleading statements about its compliance with FDA regulations or cGMP,
and thus the Second Circuit did not address the issue we face here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> We reject KV's contention that its statements about material
compliance with FDA regulations and cGMP were not false or misleading
because the Form 483s were publicly available through a Freedom of
Information Act (FOIA) request. Having chosen to represent it was in
material compliance with FDA regulations and cGMP, KV was obligated to make
a full disclosure of any material facts. <i>See K-tel</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X6BI1N?jcsearch=300%20f%203d%20881&amp;summary=yes#jcite">300 F.3d at 898</a>
(explaining that a party with no duty to speak on a particular topic must
nevertheless make a full disclosure when it chooses to speak); <i>see also</i>
<i>Sailors v. N. States Power Co.</i>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NKG9?jcsearch=4%20f%203d%20610&amp;summary=yes#jcite">4 F.3d 610</a>, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NKG9?jcsearch=4%20f%203d%20610&amp;summary=yes#jcite">612</a> (8th Cir.1993) ("A duty [to
disclose] arises . . . if there have been inaccurate, incomplete or
misleading disclosures."). If KV had chosen only to indicate that it was
regulated by the FDA, the public availability of the Form 483s may have
insulated it from a claim for securities fraud. <i>See Sailors</i>,
<a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NKG9?jcsearch=4%20f%203d%20610&amp;summary=yes#jcite">4 F.3d at 612-13</a>. KV went a step farther, however, and affirmatively
represented it was compliant with FDA regulations, giving rise to a duty to
disclose material information.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> The pleaded facts in this case are significantly different from those
involved in <i>Acito</i>, where the results of unfavorable FDA inspections were
found not to be material. <i>Acito</i> involved three FDA inspections which took
place at just one plant among thirty of the company's business locations, a
plant which produced just ten of one thousand products manufactured by the
company in over thirty countries, <a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NJ6V?jcsearch=47%20f%203d%2047&amp;summary=yes#jcite">47 F.3d at 52</a>, whereas here the investors
allege the FDA violations covered the entire range of KV's operations and
products, including generic Metoprolol, which the investors alleged was
responsible for an explosive growth in KV's earnings and sustained high
stock prices. In addition, the conditions in the plant at issue in <i>Acito</i>
improved between the first and second inspections, <i><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X2NJ6V?jcsearch=47%20F.3d%2047&amp;summary=yes#jcite">id</a>.</i>, whereas here the
investors alleged there was an eight-year history of continuing cGMP
violations which eventually led the FDA to completely shut down KV's
operations. Moreover, as we stated above, <i>Acito</i> did not involve allegations
that the company made false or misleading statements about its compliance
with FDA regulations or cGMP. <i>See ante</i> at n. 6.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> On March 10, 2011, subsequent to the district court's denial of the
motion to amend the complaint, Hermelin pleaded guilty to a criminal
information charging him with mis-branding drugs. The charges against
Hermelin repeat the allegations against "Corporate Executive A" from ETHEX's
criminal charges. Thus, by pleading guilty, Hermelin confirmed the
investors' allegations that he was the "Corporate Executive A" referred to
in the SAC. <i>See</i> Appellants' Supplemental App. at 6.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> As we noted, the criminal conduct establishing FDA violations as
early as May 2008 would also bear on whether KV's representation of FDA
compliance on June 26, 2008, was false and misleading.
</p></div>
</div>
<!--BBLS DD 1711417589763-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HPS70003/history">Direct History (12)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HPS70003/analysis">Case Analysis (12)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HPS70003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
11
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HPS70003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
1
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Order Affirmed (In Part), Order Reversed (In Part), Motion Granted, Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Securities &amp; Commodities Trading/Exchanges</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/document/X1Q6LF7SM9O2">10-03402 (8th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Securities Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/3a432f917f0c603aa8163a5e2ca2263e/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "3a432f917f0c603aa8163a5e2ca2263e";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY8d7364&previousPageId=&previousActivityInstanceId=ENTITY920547&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:48:47-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HPS70003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY920547&previousPageId=&previousActivityInstanceId=ENTITYf81486&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:48:41-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HPS70003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HPS70003";
$('#page_loader').show().spin();
JUDGE_IDS=["3028474","3593626","4211384"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
